In this issue:
VTE risk with hormone replacement therapies
Caplacizumab for acquired TTP
Tisagenlecleucel in adult relapsed/ refractory DLBCL
OS trends and clinical characteristics of plasmacytoma in the US
Double-hit gene expression signature defines distinct GCB-DLBCL subgroup
Defining a poor-risk group of molecular high-grade B-cell lymphoma
5 versus 10 days of decitabine in older newly diagnosed AML patients
Foetal haemoglobin induction during decitabine for elderly MDS/AML
Venetoclax + decitabine or azacitidine in treatment-naive elderly AML
Please login below to download this issue (PDF)